a DTaP = Diphtheria, tetanus and acellular pertussis; b IPV = Inactivated poliovirus; c Hib = Haemophilus influenzae type b. d Depending on the type of RV vaccine used, a third dose may be required.
Contraindications to vaccination with Pentacel or Quadracel vaccine include: severe allergic reaction (eg, anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine (Pentacel vaccine only); a progressive neurologic disorder; or encephalopathy within 7 days after a previous dose of a pertussis-containing vaccine with no other identifiable cause.
If Guillain-Barré syndrome has occurred within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to a previous dose of Pentacel or Quadracel vaccine or receipt of any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, the decision to give Pentacel or Quadracel vaccine should be based on careful consideration of the potential benefits and risks.
For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel vaccine and for the next 24 hours.
Apnea following intramuscular vaccination has been observed in some infants born prematurely.
The most common local and systemic adverse reactions to Pentacel vaccine include redness, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. Other adverse reactions may occur.
The most common local and systemic adverse reactions to Quadracel vaccine include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.
Vaccination with Pentacel or Quadracel vaccine may not protect all individuals.
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).
Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).
e CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.
Quadracel vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.
Quadracel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2015.
Pentacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016.
Liang J, Wallace G, Mootrey G. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep. 2015:64(34):948-949.
Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2017. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed March 30, 2017.